Clinical Trials · NCT06579105
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 406
- Start date
- Oct 2024
- Locations
- 97 sites, 9 countries
- Primary endpoint
- Change in HbA1c